A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs IONIS-SOD1Rx (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen
- 17 Jan 2018 Planned number of patients changed from 72 to 84.
- 17 Jan 2018 Planned End Date changed from 10 Jul 2018 to 2 Feb 2019.
- 17 Jan 2018 Planned primary completion date changed from 10 Jul 2018 to 2 Feb 2019.